Williams to Revive Disputed Gas Pipeline Projects in New York
The Tulsa-based company is preparing to file paperwork with federal energy regulators for both the Constitution Pipeline and Northeast Supply Enhancement project, which would transport natural gas from Pennsylvania across the Northeast, said people familiar with the matter who weren't authorized to speak publicly. Those filings could happen imminently, one of the people said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Former aide to NYC Mayor Eric Adams pleads guilty in straw donor scheme
NEW YORK — Former City Hall aide Mohamed Bahi pleaded guilty to conspiracy Tuesday for his role in organizing illegal straw donor contributions toward Eric Adams's 2021 campaign for mayor. Bahi, 41, pleaded guilty to one count of conspiracy related to wire fraud in Manhattan federal court. He admitted to helping to organize a December 2020 fundraiser at which construction company employees donated money they'd later be reimbursed. Bahi said he did so knowing Adams's campaign would be able to use the donations to seek matching funds from the city 'and that it was wrong.' In a separate case, Adams was accused of soliciting bribes and illegal contributions to both his 2021 and 2025 campaigns, mostly from Turkish government operatives. Those charges were dropped in a controversial move by President Donald Trump's Justice Department. As part of his plea deal, Bahi waived his right to appeal and agreed to pay $32,000 in restitution and between $2,000 to $20,000 in fines. The terms will be set at his sentencing, which was set for Nov. 18. ----------
Yahoo
11 minutes ago
- Yahoo
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the 'Company'), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. 'In the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD, which now includes 76 secured clinical sites across the U.S. and over 400 patients screened to date,' said Maria Maccecchini, Ph.D., President and CEO of Annovis. 'At the same time, we reached other notable milestones, including presenting our latest scientific findings at AAIC 2025 with the largest attendance ever from Annovis team and strengthening our global intellectual property protection by completing the transfer of all patent families to crystal buntanetap. As we move forward, our focus stays firmly on completing enrollment as planned to produce strong and trustworthy results, while also advancing our Parkinson's program, with more updates coming as we progress.' Clinical highlights Annovis' pivotal Phase 3 study in early AD (NCT06709014) is advancing rapidly, with 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly. The pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening – a number that continues to grow each day – with screen failure rate being as expected at 50%. Business highlights In April, Annovis welcomed Hui Liu as Director of Biostatistics, who is responsible for maintaining statistical integrity of the data generated by the Company's clinical trials. In June, Annovis hosted a webcast to provide updates on its Phase 3 trial, engaging directly with the audience through a live Q&A session. The recording is available in the Video Library on the Company's website. In July, senior members of Annovis attended AAIC 2025 in Toronto, presenting four scientific posters highlighting advancements in the Alzheimer's Phase 3 study and the pharmacokinetic profile of its lead drug candidate, buntanetap. All posters are available in the Media Library on the Company's website. In August, Annovis announced the successful transfer of all patent families to crystal buntanetap, achieving comprehensive global IP coverage for both the original and new forms of the Company's drug candidate. Financial results Annovis' cash and cash equivalents totaled $17.1 million as of June 30, 2025, compared to $10.6 million as of December 31, 2024. The Company had 19.5 million shares of common stock outstanding as of June 30, 2025. Research and development expenses for the three months ending June 30, 2025, were $5.2 million compared to $5.8 million for the three months ending June 30, 2024. General and administrative expenses for the three months ending June 30, 2025, were $1.1 million compared to $2.0 million for the three months ending June 30, 2024. Annovis reported a $0.32 basic and diluted net loss per common share for the three months ending June 30, 2025, compared to a $0.44 basic and diluted net loss per common share for the three months ending June 30, 2024. About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under 'Risk Factors' in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA Investor Contact:Alexander Morin, Strategic CommunicationsAnnovis Bioir@ (Tables to follow) ANNOVIS BIO, INC. Balance Sheets (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 17,130,286 $ 10,551,916 Prepaid expenses and other current assets 4,324,285 3,373,717 Total assets $ 21,454,571 $ 13,925,633 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 974,311 $ 2,305,974 Accrued expenses 1,830,813 1,575,013 Total current liabilities 2,805,124 3,880,987 Non-current liabilities: Warrant liability 319,000 737,000 Total liabilities 3,124,124 4,617,987 Commitments and contingencies Stockholders' equity: Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $0.0001 par value, 70,000,000 shares authorized, 19,486,231 and 14,141,521 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,948 1,414 Additional paid-in capital 164,935,088 144,155,694 Accumulated deficit (146,606,589 ) (134,849,462 ) Total stockholders' equity 18,330,447 9,307,646 Total liabilities and stockholders' equity $ 21,454,571 $ 13,925,633 ANNOVIS BIO, INC. Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,161,921 $ 5,785,217 $ 10,173,438 $ 12,307,308 General and administrative 1,109,532 1,977,421 2,380,696 3,265,137 Total operating expenses 6,271,453 7,762,638 12,554,134 15,572,445 Operating loss (6,271,453 ) (7,762,638 ) (12,554,134 ) (15,572,445 ) Other income (expense): Interest income 191,395 25,978 379,007 70,146 Other financing costs — (1,346,060 ) — (1,346,060 ) Change in fair value of warrants (140,000 ) 4,062,308 418,000 10,761,000 Total other income, net 51,395 2,742,226 797,007 9,485,086 Net loss $ (6,220,058 ) $ (5,020,412 ) $ (11,757,127 ) $ (6,087,359 ) Net loss per share Basic $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (0.56 ) Diluted $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (1.52 ) Weighted-average number of common shares used in computing net loss per share Basic 19,486,231 11,307,759 18,464,877 10,966,412 Diluted 19,486,231 11,307,759 18,464,877 11,066,265
Boston Globe
12 minutes ago
- Boston Globe
Somerville startup offers AI app to help police fight crime
After bulletins are issued, the software can use artificial intelligence to analyze multiple reports, which are often publicly available, across cities, regions, or even multiple states. The AI looks for patterns, such as the use of a similar vehicle or a breaking and entering technique, then alerts users if it links crimes from multiple reports (each department decides whether and how far afield its bulletins will be included in the AI search). The AI also tries to display relevant bulletins to each user, such as alerting a robbery detective investigating one break-in of similar prior incidents. Advertisement Multitude Insights is offering agencies software to create digital online bulletins reporting crimes and make connections between disparate incidents to catch the crooks. Multitude Insights 'If you're inside of a big [law enforcement] agency like a Boston or a Seattle, the left hand often doesn't know what the right hand is doing,' said Matt White, cofounder and chief executive, in an interview at the firm's offices near Teele Square in Somerville. 'We've taken what is a kind of an ad hoc process around the country and turned it into something that is a searchable, usable database.' Advertisement In one case, White said the company's software helped law enforcement agencies in two different states connect the same domestic terrorist group to incidents in which weather radars were destroyed. (Multitude Insights declined to disclose details of the incidents.) In another case, the system connected a string of thefts by a credit card scammer in California, thanks to a baseball cap the crook was wearing, White said. In a demonstration at Multitude's headquarters, White and chief technology officer Frank Conroy showed how a law enforcement officer could rapidly create a bulletin by selecting categories such as the type of crime from drop-down lists, fill in more details, and upload photos or videos. At the bottom of the report, other officers can leave comments or tips. Police departments using Multitude's software contacted by the Globe either declined to comment or did not respond. With cofounder Akihiko Izu, a Japanese lawyer who White met at MIT's Sloan School, Multitude's team has raised more than $5 million from investors including New York-based venture capital firm Commonweal Ventures. At a time when AI Advertisement The current mess of paper and emailed bulletins often leads to information overload and ignored reports, according to Dean Esserman, former chief of police in New Haven. And when a suspect is caught for one crime, officers rarely have time to research whether they might have been involved in other cases. 'It would be great if you had the time and no pressure to keep plodding along, trying to link other cases, other hints, other pieces of evidence or leads,' said Esserman, who now advises Multitude. 'This software can help that happen.' Before attending MIT as part of a joint program with Harvard's Kennedy school, White spent more than eight years in the Navy, crammed into the back of aircraft flying intelligence-gathering missions. He came away impressed with the armed forces' technology for analyzing intel. Then on a ride-along with Boston police during grad school, he sensed an opportunity to modernize the antiquated bulletin system. 'I spent a lot of time trying to find the signal in the noise,' White said. 'What's actually important is helping an officer get to the next important thing, not just the next thing.' Aaron Pressman can be reached at
